TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma-Reference-Cited by-同舟云学术

TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma

Published:2020-02-01 Issue:1 Volume:41 Page:53-65
ISSN:0388-6107
Container-title:Biomedical Research
language:en
Short-container-title:Biomed. Res.

Author:

KUCHITSU Yuki¹,NAGASHIO Ryo²¹,IGAWA Satoshi³,KUSUHARA Seiichiro³,TSUCHIYA Benio¹⁴,ICHINOE Masaaki⁵,SATOH Yukitoshi⁶,NAOKI Katsuhiko³,MURAKUMO Yoshiki⁵,SAEGUSA Makoto⁵,SATO Yuichi²¹

Affiliation:

1. Department of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University

2. Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University

3. Department of Respiratory Medicine, School of Medicine, Kitasato University

4. Department of Pathology, School of Allied Health Sciences, Kitasato University

5. Department of Pathology, School of Medicine, Kitasato University

6. Department of Thoracic and Cardiovascular Surgery, School of Medicine, Kitasato University

Publisher

Biomedical Research Press

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.jstage.jst.go.jp/article/biomedres/41/1/41_53/_pdf

Reference39 articles.

1. 1 Agorreta J, Hu J, Liu D, Delia D, Turley H, Ferguson DJ, Iborra F, Pajares MJ, Larrayoz M, Zudaire I, Pio R, Montuenga LM, Harris AL, Gatter K and Pezzella F (2014) TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC. Mol Cancer Res 12, 660–669.

2. 2 Altieri DC, Stein GS, Lian JB and Languino LR (2012) TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta 1823, 767–773.

3. 3 Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. N Engl J Med 350, 351–360.

4. 4 Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, Zeillinger R and Pils D (2012) Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer —a study of the OVCAD consortium. Mol Cancer 11, 69.

5. 5 Chang A (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71, 3–10.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor necrosis factor receptor–associated protein 1 (TRAP1) inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

2. The development of cancers research based on mitochondrial heat shock protein 90;Frontiers in Oncology;2023-11-30

3. Nanomagnetic bead-based nucleic acid isolation to examine the correlation of serum TRAP1 and MDSC levels with clinical treatment efficacy and prognosis in nonsmall cell lung cancer;Materials Express;2023-09-01

4. New biochemical, immune and molecular markers in lung cancer: Diagnostic and prognostic opportunities;Advances in Clinical and Experimental Medicine;2022-08-24

5. Trajectory of autoantibody-based cancer biomarker research;Electrophoresis Letters;2022